pharma · ADHD · Idiopathic Hypersomnia · ZVRA
ZEVRA THERAPEUTICS
ZEVRA THERAPEUTICS, INC.
ZEVRA THERAPEUTICS patent portfolio — 5 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2006
- Employees
- 81
- Programs
- 4
- Drugs
- 6
- Patents
- 5
ZEVRA THERAPEUTICS patents
5 pharmaceutical patents indexed for ZEVRA THERAPEUTICS. 0 expire within 24 months.
ZEVRA THERAPEUTICS has 5 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12251445
Gamma-hydroxybutyrate delivering compounds and processes for making and using them
granted -
US 12091386
D-amphetamine compounds, compositions, and processes for making and using the same
granted -
US 12076316
Levorphanol prodrugs and processes for making and using them
granted -
US 12012384
Dextrorphan prodrugs and processes for making and using them
granted -
US 11938125
Use of Hsp70 as a regulator of enzymatic activity
granted
Frequently asked questions
How many patents does ZEVRA THERAPEUTICS have?
5 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do ZEVRA THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.